Lilly starts a Phase 2b trial of macupatide and eloralintide in adults with obesity without diabetes
CombinationP1Primary public evidenceTrial registry record
NCT07589608 lists a start date of 15 May 2026 for a Phase 2b placebo-controlled study of macupatide and eloralintide, alone or in combination, in adults with obesity or overweight and without type 2 diabetes. The registry lists 400 planned participants, 40 locations and primary completion in September 2027.
400
Planned participants, as recorded in the registry
September 2027
Primary completion date listed in the registry
Background and context
How the trial is set up
The registry describes a Phase 2b, parallel-group, double-blind, placebo-controlled study of macupatide and eloralintide, alone or in combination, in adults aged 18 to 75 with obesity or overweight and without diabetes. It plans to enrol 400 people at 40 US sites and lasts about 64 weeks. It runs under Lilly master protocol CWMM (NCT06143956), which covers several weight-management studies.
Endpoints and what is not yet known
The primary endpoint is percent change in body weight at week 36, with the same measure at week 48 as a secondary endpoint. A companion Phase 2 trial in adults with type 2 diabetes (NCT07215559) plans 200 participants. This trial has no results posted, and its primary completion is registered for September 2027.
Trial records: ClinicalTrials.gov NCT07589608 and NCT07215559, read on 2026-10-15.
P1Primary public evidenceTrial registry record.An official trial registration. A registration shows that a study exists; it does not show that the compound works.
